Print this page
-
A Phase 3, Randomized, Open-Label Study of MK-5684 (004) Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA).
Protocol: 082307Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A Phase 3, Randomized, Open-Label Study of MK-5684 (004) Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA).
Protocol: 082307Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer.
Protocol: 082401Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer.
Protocol: 082401Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma.
Protocol: 082409Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma.
Protocol: 082409Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
Phase II Trial of Serum Micro RNA-371 in Detecting Active Germ Cell Tumors in Patients with Suspected Regional Disease.
Protocol: 082410Principal Investigator:
- Thomas Jang
Applicable Disease Sites: Other Urinary -
Phase II Trial of Serum Micro RNA-371 in Detecting Active Germ Cell Tumors in Patients with Suspected Regional Disease.
Protocol: 082410Principal Investigator:
- Thomas Jang
Applicable Disease Sites: Other Urinary -
A Phase II Trial of Sequential Gemcitabine and Mitomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma.
Protocol: 082411Principal Investigator:
- Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
Translational Research on Integrated Predictive Liquid and Excretory biomarkers in Urothelial Carcinoma (TRIPLE-UC).
Protocol: 082412Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
A Phase II Trial of Sequential Gemcitabine and Mitomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma.
Protocol: 082411Principal Investigator:
- Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
Translational Research on Integrated Predictive Liquid and Excretory biomarkers in Urothelial Carcinoma (TRIPLE-UC).
Protocol: 082412Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer.
Protocol: 082413Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer.
Protocol: 082413Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer.
Protocol: 082501Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer.
Protocol: 082501Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder